SKyvec™ Viral Vector Platform

Our harmonized SKyvec™ viral vector platform is designed to streamline process development, manufacturing, and scale-up across AAV, lentiviral, and adenoviral vectors, supporting gene therapy programs from early development through clinical and commercial production. Backed by global development and manufacturing capabilities, this flexible platform approach can also be adapted to additional viral vector modalities, including oncolytic viruses, herpes-viruses, retroviruses, and emerging gene therapy applications.

Our integrated capabilities span cell line and plasmid development, process development, drug substance manufacturing, and drug product manufacturing. With operations across North America and Europe and experience supporting clinical-stage programs, SKyvec™ enables efficient progression from vector design to scalable manufacturing while maintaining process consistency, process quality, and supply continuity.